Potential Impact of SGLT2 Inhibitors on Left Ventricular Diastolic Function in Patients with Diabetes Mellitus

Overview

Journal Heart Fail Rev

Date 2018 Jan 14

PMID 29330646

Citations 14

Authors

Hidekazu Tanaka

Ken-Ichi Hirata

Affiliations

Soon will be listed here.

Abstract

The pathogenesis of diabetes mellitus (DM)-related cardiac dysfunction is thought to be multifactorial, and possibly a key factor for the development of heart failure with preserved ejection fraction (HFpEF) in patients with DM and preserved left ventricular (LV) ejection fraction. Currently, there is no effective treatment for HFpEF, which is presented as LV diastolic dysfunction. Furthermore, it is well known that, in addition to DM, hypertension and overweight/obesity are also important factors associated with HFpEF. Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of diabetic medications indicated only for the treatment of type 2 DM, and a recent clinical trial showed that patients with this disease and at high risk for cardiovascular events attained cardiovascular benefits from SGLT2 inhibitor in comparison with placebo efficacy. In addition to reduction of glycated hemoglobin levels in patients with type 2 DM, SGLT2 inhibitors are associated with weight loss and reductions in blood pressure. However, despite such intriguing results, it remains uncertain whether SGLT2 inhibitors are beneficial for LV diastolic function in patients with DM. This review deals with the impact of SGLT2 inhibitors on LV diastolic function in patients with DM and their current potential for prevention of the future development of HFpEF in such patients.

Citing Articles

Potential of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Heart Failure With Preserved Ejection Fraction: A Narrative Review.

Alsuwayh A, Altawili M, Alhazmi M, Alotaibi D, Rashed A, Obaid Abdullah A Cureus. 2024; 16(11):e73906.

PMID: 39697908 PMC: 11653976. DOI: 10.7759/cureus.73906.

The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review.

Stachteas P, Nasoufidou A, Karagiannidis E, Patoulias D, Karakasis P, Alexiou S J Clin Med. 2024; 13(18).

PMID: 39336895 PMC: 11431971. DOI: 10.3390/jcm13185408.

Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review.

Panico C, Bonora B, Camera A, Chilelli N, Prato G, Favacchio G Cardiovasc Diabetol. 2023; 22(1):164.

PMID: 37391739 PMC: 10314539. DOI: 10.1186/s12933-023-01855-y.

Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trial.

Prochaska J, Junger C, Schulz A, Arnold N, Muller F, Heidorn M Clin Res Cardiol. 2023; 112(7):911-922.

PMID: 36763159 PMC: 10293456. DOI: 10.1007/s00392-023-02164-w.

The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with heart failure with reduced ejection fraction.

Maragkoudakis S, Marketou M, Katsi V, Patrianakos A, Tsigkriki L, Mamaloukaki M Arch Med Sci Atheroscler Dis. 2021; 6:e176-e181.

PMID: 34703947 PMC: 8525245. DOI: 10.5114/amsad.2021.109685.

References

Boyer J, Thanigaraj S, Schechtman K, Perez J . Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol. 2004; 93(7):870-5. DOI: 10.1016/j.amjcard.2003.12.026. View

Ernande L, Rietzschel E, Bergerot C, De Buyzere M, Schnell F, Groisne L . Impaired myocardial radial function in asymptomatic patients with type 2 diabetes mellitus: a speckle-tracking imaging study. J Am Soc Echocardiogr. 2010; 23(12):1266-72. DOI: 10.1016/j.echo.2010.09.007. View

Ernande L, Bergerot C, Girerd N, Thibault H, Davidsen E, Gautier Pignon-Blanc P . Longitudinal myocardial strain alteration is associated with left ventricular remodeling in asymptomatic patients with type 2 diabetes mellitus. J Am Soc Echocardiogr. 2014; 27(5):479-88. DOI: 10.1016/j.echo.2014.01.001. View

Paulus W, van Ballegoij J . Treatment of heart failure with normal ejection fraction: an inconvenient truth!. J Am Coll Cardiol. 2010; 55(6):526-37. DOI: 10.1016/j.jacc.2009.06.067. View

Haring H, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle H . Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013; 36(11):3396-404. PMC: 3816918. DOI: 10.2337/dc12-2673. View

Ryden L, Grant P, Anker S, Berne C, Cosentino F, Danchin N . ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in.... Eur Heart J. 2013; 34(39):3035-87. DOI: 10.1093/eurheartj/eht108. View

Di Bonito P, Moio N, Cavuto L, Covino G, Murena E, Scilla C . Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabet Med. 2006; 22(12):1720-5. DOI: 10.1111/j.1464-5491.2005.01685.x. View

Packer M . Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. Circ Heart Fail. 2011; 4(5):538-40. DOI: 10.1161/CIRCHEARTFAILURE.111.963710. View

Zoroufian A, Razmi T, Taghavi-Shavazi M, Lotfi-Tokaldany M, Jalali A . Evaluation of subclinical left ventricular dysfunction in diabetic patients: longitudinal strain velocities and left ventricular dyssynchrony by two-dimensional speckle tracking echocardiography study. Echocardiography. 2013; 31(4):456-63. DOI: 10.1111/echo.12389. View

10.

Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle H . Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014; 37(7):1815-23. DOI: 10.2337/dc13-3055. View

11.

Holland D, Kumbhani D, Ahmed S, Marwick T . Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J Am Coll Cardiol. 2011; 57(16):1676-86. DOI: 10.1016/j.jacc.2010.10.057. View

12.

Sharma G, Woods P, Lambrew C, Berg C, Pietro D, Rocco T . Evaluation of a noninvasive system for determining left ventricular filling pressure. Arch Intern Med. 2002; 162(18):2084-8. DOI: 10.1001/archinte.162.18.2084. View

13.

Bhuiyan T, Maurer M . Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma. Curr Cardiovasc Risk Rep. 2011; 5(5):440-449. PMC: 3211140. DOI: 10.1007/s12170-011-0184-2. View

14.

Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Drazner M . 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62(16):e147-239. DOI: 10.1016/j.jacc.2013.05.019. View

15.

Tadic M, Ilic S, Cuspidi C, Stojcevski B, Ivanovic B, Bukarica L . Left Ventricular Mechanics in Untreated Normotensive Patients with Type 2 Diabetes Mellitus: A Two- and Three-dimensional Speckle Tracking Study. Echocardiography. 2014; 32(6):947-55. DOI: 10.1111/echo.12790. View

16.

Holland D, Marwick T, Haluska B, Leano R, Hordern M, Hare J . Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus. Heart. 2015; 101(13):1061-6. DOI: 10.1136/heartjnl-2014-307391. View

17.

Sacre J, Franjic B, Jellis C, Jenkins C, Coombes J, Marwick T . Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. JACC Cardiovasc Imaging. 2010; 3(12):1207-15. DOI: 10.1016/j.jcmg.2010.09.014. View

18.

Shah A, Pfeffer M . The many faces of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2012; 9(10):555-6. DOI: 10.1038/nrcardio.2012.123. View

19.

Solomon S, Claggett B, Lewis E, Desai A, Anand I, Sweitzer N . Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2015; 37(5):455-62. PMC: 4751235. DOI: 10.1093/eurheartj/ehv464. View

20.

Nakai H, Takeuchi M, Nishikage T, Lang R, Otsuji Y . Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration. Eur J Echocardiogr. 2009; 10(8):926-32. DOI: 10.1093/ejechocard/jep097. View